SIRT6 protects vascular smooth muscle cells from osteogenic transdifferentiation via Runx2 in chronic kidney disease. 2022

Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
Department of Cardiology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.

Vascular calcification (VC) is regarded as an important pathological change lacking effective treatment and associated with high mortality. Sirtuin 6 (SIRT6) is a member of the Sirtuin family, a class III histone deacetylase and a key epigenetic regulator. SIRT6 has a protective role in patients with chronic kidney disease (CKD). However, the exact role and molecular mechanism of SIRT6 in VC in patients with CKD remain unclear. Here, we demonstrated that SIRT6 was markedly downregulated in peripheral blood mononuclear cells (PBMCs) and in the radial artery tissue of patients with CKD with VC. SIRT6-transgenic (SIRT6-Tg) mice showed alleviated VC, while vascular smooth muscle cell-specific (VSMC-specific) SIRT6 knocked-down mice showed severe VC in CKD. SIRT6 suppressed the osteogenic transdifferentiation of VSMCs via regulation of runt-related transcription factor 2 (Runx2). Coimmunoprecipitation (co-IP) and immunoprecipitation (IP) assays confirmed that SIRT6 bound to Runx2. Moreover, Runx2 was deacetylated by SIRT6 and further promoted nuclear export via exportin 1 (XPO1), which in turn caused degradation of Runx2 through the ubiquitin-proteasome system. These results demonstrated that SIRT6 prevented VC by suppressing the osteogenic transdifferentiation of VSMCs, and as such targeting SIRT6 may be an appealing therapeutic target for VC in CKD.

UI MeSH Term Description Entries
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D010012 Osteogenesis The process of bone formation. Histogenesis of bone including ossification. Bone Formation,Ossification, Physiologic,Endochondral Ossification,Ossification,Ossification, Physiological,Osteoclastogenesis,Physiologic Ossification,Endochondral Ossifications,Ossification, Endochondral,Ossifications,Ossifications, Endochondral,Osteoclastogeneses,Physiological Ossification
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D050659 Core Binding Factor Alpha 1 Subunit A transcription factor that dimerizes with CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain and is involved in genetic regulation of skeletal development and CELL DIFFERENTIATION. AML3 Transcription Factor,Acute Myeloid Leukemia 3 Protein,CBFA-1 Protein,CBFA1 Protein,CBFalpha Runt Domain Transcription Factor 1,CBFalpha1 Protein,Osf2 Transcription Factor,PEBP2alphaA Protein,Runx2 Protein,SEF1 Protein,SL3-3 Enhancer Factor 1,CBFA 1 Protein,SL3 3 Enhancer Factor 1
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D051436 Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002) Kidney Insufficiency, Chronic,Chronic Kidney Diseases,Chronic Kidney Insufficiency,Chronic Renal Diseases,Chronic Renal Insufficiency,Chronic Kidney Disease,Chronic Kidney Insufficiencies,Chronic Renal Disease,Chronic Renal Insufficiencies,Disease, Chronic Kidney,Disease, Chronic Renal,Diseases, Chronic Kidney,Diseases, Chronic Renal,Kidney Disease, Chronic,Kidney Diseases, Chronic,Kidney Insufficiencies, Chronic,Renal Disease, Chronic,Renal Diseases, Chronic,Renal Insufficiencies, Chronic
D054338 Cell Transdifferentiation A naturally occurring phenomenon where terminally differentiated cells dedifferentiate to the point where they can switch CELL LINEAGES. The cells then differentiate into other cell types. Transdifferentiation, Cell,Cell Transdifferentiations,Transdifferentiations, Cell
D055785 Gene Knockdown Techniques The artificial induction of GENE SILENCING by the use of RNA INTERFERENCE to reduce the expression of a specific gene. It includes the use of DOUBLE-STRANDED RNA, such as SMALL INTERFERING RNA and RNA containing HAIRPIN LOOP SEQUENCE, and ANTI-SENSE OLIGONUCLEOTIDES. Gene Knock Down Techniques,Gene Knock Down,Gene Knock-Down,Gene Knock-Down Techniques,Gene Knockdown,Gene Knock Downs,Gene Knock-Down Technique,Gene Knock-Downs,Gene Knockdown Technique,Gene Knockdowns,Knock Down, Gene,Knock Downs, Gene,Knock-Down Technique, Gene,Knock-Down Techniques, Gene,Knock-Down, Gene,Knock-Downs, Gene,Knockdown Technique, Gene,Knockdown Techniques, Gene,Knockdown, Gene,Knockdowns, Gene,Technique, Gene Knock-Down,Technique, Gene Knockdown,Techniques, Gene Knock-Down,Techniques, Gene Knockdown

Related Publications

Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
February 2024, iScience,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
April 2023, Molecular biology reports,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
December 2022, Renal failure,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
December 2022, Renal failure,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
January 2015, BioMed research international,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
March 2014, Kidney international,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
July 2023, Molecular biology reports,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
September 2023, Molecular biology reports,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
February 2021, Circulation research,
Wenxin Li, and Weijing Feng, and Xiaoyan Su, and Dongling Luo, and Zhibing Li, and Yongqiao Zhou, and Yongjun Zhu, and Mengbi Zhang, and Jie Chen, and Baohua Liu, and Hui Huang
January 2019, Scientific reports,
Copied contents to your clipboard!